Dalbavancin hydrochloride

盐酸达巴万星

Report date: 2026/05/26 20:00:28
NMEQIDP

Base Information

Drug NameDalbavancin hydrochloride
Drug Alias Namedalbavancina道古霉素dalbavancine达贝万星达巴凡星 +[16] 
ClassificationSmall molecules > Heterocyclic drugs > AntibioticsSmall molecules > Heterocyclic drugs > Antibiotics > Glycopeptide antibiotics
Mechanisms of ActionPeptidoglycan inhibitorsCell wall inhibitors
TargetsPeptidoglycan
Therapy Area/IndicationsAcute bacterial skin and skin structure infectionsSubstance Abuse, IntravenousSubstance-Related Disorders +[15] 
Global Approved IndicationsAcute bacterial skin and skin structure infectionsSkin Diseases, Bacterial
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2014/05/23
Country/TerritoryBulgariaCanadaUnited States +[22] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesActavis
China Registration ClassN/A

Develop Information

Active CompaniesRaqualia Pharma IncAbbvie IncAbbvie Deutschland Gmbh & Co Kg +[6] 
Inactive CompaniesVicuron PharmaceuticalsDurata Therapeutics Inc., An Affiliate Of Allergan PlcPfizer Inc +[6] 
Active IndicationsAcute bacterial skin and skin structure infectionsSkin Diseases, BacterialStreptococcal Infections +[4] 
Inactive IndicationsSubstance Abuse, IntravenousSubstance-Related DisordersEndocarditis +[11] 

Other Information

ATC CodeJ01XA04
Related LinksWikipediaDrugBankKEGG